These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 3573331)

  • 21. Immune reactive factor IX in acquired factor IX deficiency.
    Lechner K
    Thromb Diath Haemorrh; 1972 Feb; 27(1):19-24. PubMed ID: 5033668
    [No Abstract]   [Full Text] [Related]  

  • 22. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine.
    Chao H; Walsh CE
    Thromb Haemost; 1999 Oct; 82(4):1378. PubMed ID: 10544943
    [No Abstract]   [Full Text] [Related]  

  • 24. Bovine factor IX (Christmas factor).
    Fujikawa K; Davie EW
    Methods Enzymol; 1976; 45():74-83. PubMed ID: 1012029
    [No Abstract]   [Full Text] [Related]  

  • 25. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A factor IX-concentrate for the treatment of haemophilia B].
    Suomela H; Myllylä G
    Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
    [No Abstract]   [Full Text] [Related]  

  • 29. Acquired factor IX inhibitor in a patient with Christmas disease: case report.
    Riyat MS; Kasili EG; Omondi BE
    East Afr Med J; 1984 Feb; 61(2):159-62. PubMed ID: 6468323
    [No Abstract]   [Full Text] [Related]  

  • 30. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.
    Bigger BW; Siapati EK; Mistry A; Waddington SN; Nivsarkar MS; Jacobs L; Perrett R; Holder MV; Ridler C; Kemball-Cook G; Ali RR; Forbes SJ; Coutelle C; Wright N; Alison M; Thrasher AJ; Bonnet D; Themis M
    Gene Ther; 2006 Jan; 13(2):117-26. PubMed ID: 16163377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
    Limentani SA; Gowell KP; Deitcher SR
    Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hemophilia B Leyden].
    Briët E; van Leeuwen-Cornelisse IS; van der Vlerk D; van Tilburg NH
    Ned Tijdschr Geneeskd; 1986 Jul; 130(29):1324-7. PubMed ID: 3748213
    [No Abstract]   [Full Text] [Related]  

  • 33. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluating the potential benefits of the extravascular pool of factor IX.
    Lillicrap D
    Blood Coagul Fibrinolysis; 2021 Jan; 32(1):68-69. PubMed ID: 33170819
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic effects of hepatocyte transplantation on hemophilia B.
    Tatsumi K; Ohashi K; Shima M; Nakajima Y; Okano T; Yoshioka A
    Transplantation; 2008 Jul; 86(1):167-70. PubMed ID: 18622295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Congenital deficiency of plasma thromboplastin component (PTC-factor IX): report of 25 cases from 19 unrelated families.
    Agarwal MB; Mehta BC
    J Assoc Physicians India; 1982 Jan; 30(1):17-9. PubMed ID: 6820363
    [No Abstract]   [Full Text] [Related]  

  • 40. Orthotopic liver transplantation for hepatitis C infection: the best Christmas present?
    Johnston SD; McNulty O; Mayne E; Callender ME
    Ulster Med J; 1998 Nov; 67(2):134-6. PubMed ID: 9885554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.